

Drug resistant Gram negative pathogens: local epidemiology & control measures

1 Jun 2010

Hospital Visits on 31 May 2010

- PWH & QEH
- At each hospital, materials to be covered:
 - Visit to clinical areas with high prevalence/ hx of clustering of drug resistant G- bugs (ICU, selected medical wards,...)
 - Discussion on the
 - prevailing practice of respective ICT on surveillance, IC and outbreak mx (if any) for drug resistant G- bugs
 - practical difficulties encountered and exploration on potential solution
 - comments and suggestions from Dr. Perl

Prince of Wales Hospital
1303 Patient beds;
Affiliated to the Chinese University
of HK



Courtesy of Infection Control Team, PWH

Infection Control Team In PWH

- 1 Infection Control Officer (also the Chief of Service of the Department of Microbiology and the Cluster ICO)
- 6 Infection Control Nurses

Cumulative Report on Antibiotic Susceptibility, PWH, 2009

Commonly isolated gram negative bacteria		Ampicillin	Piperacillin	Ampicillin / Sulbactam	Amoxicillin / Clavulanate	Piperacillin/Tazobactam	Cefoperazone/Sulbactam	Ticarcillin / Clavulanic acid	Cefuroxime (Oral)	Cefuroxime (Parenteral)	Cefotaxime	Ceftazidime	Cefepime	Cotrimoxazole	Nitrofurantoin	Gentamicin	Amikacin	Ciprofloxacin	Imipenem	Meropenem	ESBL
Isolates from all specimen from all units, PWH, 2009																					
<i>E. Coli</i>	no. sensitive	1080			2917	3508	3369		1187	2896	3015		985	2219	2529	2720	3903	2591	3948		910
	no. tested	3947			3948	3946	3948		2639	3948	3948		1309	3841	2639	3948	3947	3948	3948		3948
	% sensitive	27			74	89	85		45	73	76		75	58	96	69	99	66	100		23
<i>Klebsiella spp</i>	no. sensitive				937	1049	1097		290	943	1050		611	876	319	1114	1219	1008	1231		157
	no. tested				1231	1231	1231		529	1231	1231		702	1167	529	1231	1231	1231	1231		1231
	% sensitive				76	85	89		55	77	85		87	75	60	90	99	82	100		13
<i>Pseudomonas aeruginosa</i>	no. sensitive		1101			1107	1039	956				1109	1090			1127	1140	1055	1107	1132	
	no. tested		1155			1155	1155	1154				1155	1155			1155	1155	1155	1154	1154	
	% sensitive		95			96	90	83				96	94			98	99	91	96	98	
<i>Acinetobacter spp</i>	no. sensitive			263		239	276	232				260	254			254	311	230	293	284	
	no. tested			343		343	343	343				343	342			343	343	343	343	343	
	% sensitive			77		70	80	68				76	74			74	91	67	85	83	


Courtesy of Infection Control Team, PWH

Cumulative Report on Antibiotic Susceptibility, PWH, 2009

Commonly isolated gram negative bacteria		Ampicillin	Piperacillin	Ampicillin / Sulbactam	Amoxicillin / Clavulanate	Piperacillin/Tazobactam	Cefoperazone/Sulbactam	Ticarcillin / Clavulanic acid	Cefuroxime (Oral)	Cefuroxime (Parenteral)	Cefotaxime	Ceftazidime	Cefepime	Cotrimoxazole	Nitrofurantoin	Gentamicin	Amikacin	Ciprofloxacin	Imipenem	Meropenem	ESBL
Isolates from all specimens from ICU, PWH, 2009																					
<i>Pseudomonas aeruginosa</i>	no. sensitive		59			59	54	52				59	58			59	60	58	57	58	
	no. tested		61			61	61	61				61	61			61	61	61	61	61	
	% sensitive		97			97	89	85				97	95			97	98	95	93	90	
<i>Acinetobacter spp</i>	no. sensitive			20		19	23	18				21	21			21	31	20	29	30	
	no. tested			37		37	37	37				37	37			37	37	37	37	37	
	% sensitive			54		51	62	49				57	57			57	84	54	78	81	
<i>Klebsiella spp</i>	no. sensitive				60	62	64		3	62	64		61	63	4	69	74	66	74		8
	no. tested				74	74	74		5	74	74		69	73	5	74	74	74	74		74
	% sensitive				81	84	86		60	84	86		88	86	80	93	100	89	100		11
<i>E. Coli</i>	no. sensitive	8			28	34	33		8	30	33		22	31	15	35	60	34	61		28
	no. tested	61			61	61	61		15	61	61		46	59	15	61	61	61	61		61
	% sensitive	13			46	56	54		53	49	54		48	53	100	57	98	56	100		46

Courtesy of Infection Control Team, PWH

HA Definition for MDRA



Definition for Multidrug Resistant Acinetobacter species in PWH

Resistant to
Ceftazidime


+

At least 3 of the followings:

- Imipenem,
- Piperacillin / tazobactam,
- Cefoperazone / sulbactam
- Ticacillin,
- Ciprofloxacin
- Gentamicin
- Amikacin


PWH definition: Multidrug Resistant Acinetobacter species

Total no. of MRAB isolated in PWH
(after 48 hours of admission)




PWH definition: Multidrug Resistant Acinetobacter species

MRAB isolated after 48 hours of admission
(per 1000 patient bed days), ICU, PWH



PWH definition: Multidrug Resistant Acinetobacter species

MRAB isolated after 48 hours of admission (MRAB >48 hrs), per 1000 patient bed day by department, excluded ICU




HA definition: Multidrug Resistant

Acinetobacter species

Quarterly	Number of cases	Department
Q1 2009	0	0
Q2 2009	0	0
Q3 2009	3	M&T: 3
Q4 2009	2	M&T: 1 ICU: 1
Q1 2010	0	0

Definition for Multiple-drugs Resistant *Pseudomonas aeruginosa* (MRPA)




Multiple-drugs Resistant *Pseudomonas aeruginosa* (MRPA)

Quarterly	Number of cases	Department
Q1 2009	0	
Q2 2009	1	Surg: 1
Q3 2009	1	M&T: 1
Q4 2009	1	ICU: 1
Q1 2010	0	

Prevalence of ESBL producing E coli in PWH

ESBL producing Ecoli, isolated after 48 hours of admission (>48 hours)
per 1000 patient bed day
by Department, PWH, Quarterly Report




	>48	<48 + >48
Q2 2009	51	202
Q3 2009	48	244
Q4 2009	43	230
Q1 2010	55	269

***Around 900-1000 new isolations per year

Prevalence of ESBL producing Klebsiella in PWH


ESBL producing Klebsiella isolated after 48 hours of admission (>48 hurs), per 1000 Patient Day by Department, PWH, Quarterly Report



	>48	<48 + >48
Q2 2009	15	33
Q3 2009	21	54
Q4 2009	15	47
Q1 2010	14	46

***Around 250 new isolations per year

Workflow of Infection Control Monitoring for Alert Organism



Courtesy of Infection Control Team, PWH

Date Collected: 20/05/10 12:09
Date Arrived: 20/05/10 16:29
Specimen:- MID-STREAM URINE

Sample of laboratory result

Microscopy : Moderate numbers of WBC seen (10,000 - 100,000 cells/ml)
RBC not seen
Epithelial cells seen
Bacteria present

Routine culture :-

Organism 1 : > 100,000 CFU/ml of Escherichia coli isolated

Sensitive to:

Cotrimoxazole
Nitrofurantoin

Gentamicin
Piperacillin/tazobactam

Intermediate to:

Amoxicillin/clavulanate

Cefoperazone/sulbactam

Resistant to:

Ampicillin
Ceftazidime
Cefuroxime (parenteral)

Cefotaxime
Cefuroxime (oral)
Ciprofloxacin

ESBL positive

*** Extended-spectrum B-lactamase (ESBL) producing strain isolated. ***

Carbapenems should be regarded as the drugs of choice for serious infections with ESBL-producing organisms.

CONTACT PRECAUTION IS REQUIRED. FOR ENQUIRIES, PLEASE CONTACT INFECTION CONTROL TEAM.

Signed By: MR. CHEUNG SIU WAI

Courtesy of Infection Control Team, PWH

*** This Laboratory is accredited by NATA (Accreditation No. 14140) ***


Infection Control Measures for MDRO

- Isolate the patients in single room if possible, if not available place in corner bed or cohort together
- Contact precautions – wear gloves and disposable gowns during close patient contact
- Perform hand hygiene after removal of gloves
- Dedicated use of equipments such as stethoscopes, BP Cuff
- Environmental disinfection with 1000ppm hypochlorite solution
- MDRA / MRPA – Dedicated mop, bucket or other cleansing equipments
- MDRA / MRPA - Tagging in the CMS (Computer Management System) so that contact precautions are to be taken on re-admission

Other measures - Audit for ESBL producing organism

Audit items included

- ✓ CP signage
- ✓ Alcohol handrub at bedside
- ✓ Designated equipment
- ✓ PPE for close contact



Sharing of epidemiology of the Alert organisms (including the MDROs) to frontline colleagues

Type of report	Content	Target group
Departmental report (Monthly)	The number of new isolations of alert organisms by month	COSs, DOMs
Quarterly report (Quarterly)	The rate of hospital acquired infection of selected alert organisms and related audit result Presented in the quarterly Infection Control Committee Meeting	COSs, DOMs, DICCs

Report sample

Type of organisms

Department of Surgery Year 2010
New Methicillin resistant Staphylococcus aureus (MRSA) (Total) Monthly By Ward

WARD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov
3L	1	2	4								
3LB	0	0	0								
3M	1	1	1								
3E	0	1	1								
3F	2	1	0								
3G	1	0	0								
4KH	0	1	0								
4L	1	1	0								
4M	0	0	2								
7L	0	0	0								
7M	1	0	1								
7H	0	0	0								
7PH	0	2	0								
6K	0	0	0								
6KCC	0	0	0								
6KCN	0	0	0								
TOTAL	1	9	10								

Department of Clin
New Methicillin resistant Staphylococcus aureus (MRSA) Monthly By Ward

WARD	Jan	Feb	Mar	Apr	May
4E	1	0	0		
4F	1	0	0		
TOTAL	2	0	0		

New Methicillin resistant Staphylococcus aureus (MRSA) Monthly By Ward

WARD	Jan	Feb	Mar	Apr	May
4E	1	0	0		
4F	1	0	0		
TOTAL	2	0	0		



New Methicillin resistant Staphylococcus aureus (MRSA) Monthly By Ward

WARD	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov
6H	0	0	0								
6K	0	0	1								
6L	0	0	0								
6M	0	0	0								
6MA	0	0	0								
7H	0	0	0								
7K	0	0	0								
CCC	0	0	0								
BMT	0	0	0								
TOTAL	0	0	1								

Departmental report

IC Measures Audit of MRSA Cases in Oncology

Audit Items	Q1 2008	Q2 2008	Q3 2008	Q4 2008	Q1 2009	Q2 2009	Q3 2009	Q4 2009
1. CP Signage at bedside	3/3	2/2	NA	3/3	1/1	2/2	3/3	1/1
	100%	100%	NA	100%	100%	100%	100%	100%
2. Alcohol handrub a/v at bed end	3/3	2/2	NA	3/3	1/1	2/2	3/3	1/1
	100%	100%	NA	100%	100%	100%	100%	100%
3. Designated equipment or disinfect after use	2/3	2/2	NA	3/3	1/1	2/2	3/3	1/1
	67%	100%	NA	100%	100%	100%	100%	100%
4. PPE for close contact	1/2	2/2	NA	2/2	0/0	2/2	1/1	1/1
	50%	100%	NA	100%	0%	100%	100%	100%



Quarterly report

Environmental cleaning schedule




Locations	Cleaning frequency for the patient surrounding environment
General patient	Daily
Patient with contact precautions	Twice daily

Additional IC measures for clustering / outbreak

- Isolate/ cohorted affected patient
- Comprehensive cleaning after isolation of the patients
- Patient screening (same cubicle or the whole wards depending on the extent of involvement)
- Environmental screening – commonly touched areas
- Review of hand hygiene practices
- Outbreak meeting with the clinical management

Training for frontline staff

Infectious Disease Control Training Centre
Hospital Authority / Infection Control Branch
(CHP) August 2006

Items and Descriptions	Isolation Precautions Signage (example*)	Usage
1. PVC Signage Card <ul style="list-style-type: none"> Size: 132mm x 132mm Materials: PVC Card <ol style="list-style-type: none"> Droplet Precautions Contact Precautions 		For placing near patients' bed
2. PVC Signage Card <ul style="list-style-type: none"> Size: 170mm x 180mm With 4 small holes on top Materials: PVC card <ol style="list-style-type: none"> Droplet Precautions Contact Precautions Airborne Precautions 		For displaying on the door of isolation room
3. Art Card Signage <ul style="list-style-type: none"> Size: A5 Materials: 210 gsm matt art paper <ol style="list-style-type: none"> Droplet Precautions Contact Precautions Airborne Precautions 		

Type of Isolation Precautions	Examples	Patients Placement	Hand Washing	Mask	Eye Protection	Gown	Gloves	Patient Care Equipments	Patient Transport
Contact Precautions	MRSA, Scabies, GE	Single room or Cohort in a room/ main ward	SP	SP	SP	When anticipating close contact with patient	Whenever contact with patient	Designated or disfect after every patient use	Limit for essential purpose; Notify receiving area
Droplet Precautions	Influenza, Pertussis, Rubella	Single room or at least 3 feet apart from adjacent patients	SP	Surgical Mask (Within 3 feet of patient)	SP	SP	SP	Designated or disfect after every patient use	Patient should wear surgical mask
			SP	N95 Respirator	SP	SP	SP	Designated or disfect after every patient use	Patient should wear surgical mask



Required every 18 months

Specific training sessions

Acinetobacter

What is Acinetobacter

- Commonly found in hospital environments
- Able to survive on dry surfaces for long periods
- Most common cause of hospital-acquired pneumonia among persistently care personnel

What's ESBL producing organism?
Extended Spectrum Beta- Lactamases

Resistance to
Extended-spectrum
Beta-lactams



Multi-drug Resistant Acinetobacter Infections

Resistant to

- Fortum(Ceftazidime)

At least three of follow

- Amikin(Amikacin)
- Ciprofloxacin
- Sulperazon (Cepfoperon)
- Tazocin(Piperacillin/taz)

Risk Factors of ESBLs infection

- Prolonged hospitalization
- Prolonged ICU stays
- Long-term care facility residency
- Exposure to ceftazidime or aztreonam
- Number of antibiotics received
- Emergency abdominal surgery
- Gut colonization
- Indwelling catheter
- Ventilator dependence
- Age<12 wks
- Severity of illness

ESBL information sheet (Oncology) Aug 08.pdf - Adobe Reader

Infected Control Information (Oncology Department)

Infection Control Express

What's ESBL producing organism?

ESBL stands for Extended Spectrum Beta-Lactamases. Beta-lactamases is an enzyme which acts to hydrolyse extended spectrum cephalosporins with an oxymino side chain. These cephalosporins include cefotaxime, ceftazidime and ceftazidime. Many problems with these resistant strains are difficult in detecting the presence of ESBLs, limited treatment options and sometimes impact on critical outcomes. The infections caused by ESBLs, can sometimes progress to cause more serious infections such as long persistence which take to the treatment.

The type of bacteria which commonly produce ESBLs, are those that are classified as 'gram negative' bacteria. Strains of gram negative bacteria that are naturally present in the human digestive system are E. coli, Klebsiella and Serratia species.

Mode of Transmission: Direct and Indirect Contact

The spread of ESBLs, E. coli in a facility occurs most commonly through direct contact with someone with ESBLs, a contaminated environment or on the hands of some care providers. Besides poor personal hygiene, especially after using the washroom, can spread the bacteria from the bowel of one carrier or infected patient to the mouth of another patient.

Prevention tips

- Early detection
- Early isolation with contact precautions
- Good hand hygiene
- Avoid unnecessary use of antibiotics

When you are caring the colonized or infected ESBL patient, you should

- Play strict attention to hand hygiene
- Wear protective gown, gloves when in contact with patient
- Thoroughly disinfect all equipment between use
- Maintain high standards of environmental cleanliness especially common touch area

When to discontinue the contact precautions?

Until cultures from colonizers / infected site are negative

If further information required, please contact Infection Control Nurse Eric23161206

Risk Factors

- Prolonged hospitalization
- Prolonged ICU stay
- Long-term care facility residency
- Exposure to ceftazidime or aztreonam
- Exposure to aminoglycosides
- Number of antibiotics received
- Emergency abdominal surgery
- Gut colonization
- Indwelling catheter
- Disturbance or colonization
- Ventilator dependence
- Age<12 wks
- Low birth weight
- Transcatheter tube
- Severity of illness

When there is clustering or increase in the incidence


Antibiotics Stewardship Program

- Target to “big gun antibiotics” – carbapenems, ceftazidime, piperacillin / tazobactam, cefoperazone / sulbactam, IV quinolones, vancomycin, linezolid
- List of items used by wards are generated by pharmacy
- Concurrent feedback by daily review
- Manpower problems

Summary of Hand Hygiene Audit result 2009

- Adopted WHO HH Audit tool since 2007
- Targeted department: 7 (M&T, Surg, O&T, ICU, O&G, Paed & Oncology)
- Total opportunities: 1737
- Overall compliance in 2009: 64%


Overall Hand Hygiene Compliance of PWH (By Department)



Departments

Courtesy of Infection Control Team, PWH

Overall Hand Hygiene Compliance of PWH (By Rank)



Departments

<u>Questions/ Issues</u>	ICT	Dr. Perl:
<p>1.Hand hygiene compliance is relatively low among physicians, ~ 40%</p>	<p>It is identified that the most non-compliant moment is <u>before patient contact</u>, such as before wound inspection. Feedbacks to departments were made.</p>	<p>➤ It is better to review if there are any deficits on</p> <ol style="list-style-type: none"> 1.Knowledge 2.Attitude 3.Behavior 4.Culture 5.HH facilities <p>➤ Identified the problems and try to change the culture by behavioral change; physicians should took the lead.</p> <p>➤ HH audit and checklist serve as objective tools to reduce confrontation, but they do not influence much on culture/behavior change. Feedback mechanism is very important.</p> <p>➤ Some examples to drive change:</p> <ul style="list-style-type: none"> - “Competition” among departments - Bonus system
<p>2. Definition on GN resistance organism</p>	<p>Is any standard definition in US?</p>	<p>No standard definition among US hospitals</p>

<p>3. Chlorhexidine bathing</p>	<p>1. What is the view on using Chlorhexidine bathing as a routine practice? 2. Have taken a trial period in PWH ICU, from the preliminary observation, there was an increase in MDRA</p>	<p>In JH, it's been implemented in the adult ICU and benefit in reducing nosocomial infection have been demonstrated. Study are being carried out in paed. ICU currently.</p>
<p>4. Curtain</p>	<p>As a role of reservoir/ transmission of DNR pathogens</p>	<p>In US hospitals, wards are mostly composed of double bed rooms, so not really known if curtain is a big issue. Change curtain daily for norovirus, CD cases</p>
<p>5. Disinfection: Hydrogen peroxide vaporization</p>	<p>What is the view of using it as chemical disinfection?</p>	<p>It is used for environmental disinfection. Patients have to be removed temporarily but equipment can be left in ward.</p>

Queen Elizabeth Hospital


- The only acute hospital in KCC
- ~1775 beds
- Departments include:
medical, surgical, orthopedics, CTS, NS,
pediatrics, obstetrics & gynecological,
oncology, & Intensive care unit

Adult Intensive care unit (ward B6 & D6)


- 16 ICU beds + 2 HDU beds
- No. of patient admission per month in average : 96
- No. of patient days per month in average: 493

Data source: EIS, CDARS Jan to Dec 2009


ICU Susceptibility Data: *Escherichia coli*



ICU Susceptibility Data: P. aeruginosa



ICU Susceptibility Data: Acinetobacter spp



Surveillance Data & Trends of Drug Resistant Gram Negative pathogens

Multiple-Drug Resistant *Pseudomonas aeruginosa* (MRPA)

- Defined as co-resistant to Imipenem, Ceftazidime, Amikacin, Ciprofloxacin

Year	2002	2003	2004	2005	2006	2007	2008	2009
No. of new MRPA cases in QEH	79	82	50	8	5	1	1	0

- **“Find And Confine”**
- Active surveillance culture were done of all high risk groups, on sputum, urine, wound from ICU and ventilator ward patients;
- Communication and cooperation with cluster hospitals (BH &KH) for inter-hospital transfer of MRPA patients
- Isolate in single room until 3 consecutive negative cultures in weekly intervals

Definitions of Multiple-drugs Resistant *Acinetobacter* species (MDRA) in QEH

MDRA

- Co-resistant to all seven antibiotics (in four classes)


p-MDRA

- resistant to 3 out of 4 classes of antibiotics


Classes of Antibiotics	Antibiotic Agents
Fluoroquinolones	Ciprofloxacin Ofloxacin
Aminoglycosides	Amikacin
Cephalosporins	Ceftazidime Cefepime
Beta-lactam & beta-lactamase inhibitor combinations	Ampicillin-sulbactam Sulperazone

- Carbapenems are not included in the MDRA criteria


Nosocomial MDRA cases by specialty



No. of patents acquired MDRA (Infection+Colonization) in ICU (B6/ D6)




No. of patents acquired p-MDRA (Infection+Colonization) in ICU (B6/ D6)




Reduced susceptibility towards carbapenems & carbapenemase production

Isolate demonstrates reduced susceptibility towards carbapenems and carbapenemase production in QEH since 2007 to 2010



Reduced susceptibility towards carbapenems & carbapenemase production

Isolate demonstrates reduced susceptibility towards carbapenems and carbapenemase production by department



Infection Control Measures

SP + CP

- Patient placement
- Hand Hygiene
- PPE
- Dedicate use of equipment
- Environmental decontamination
- Patient tracking in CMS

Strategic Plan

- Collaborate with ICT and ICU
- To minimize the risk of MDRO cross transmission

Hand Hygiene enhancement

- On-going monitoring compliance rate
- Specified Hand hygiene program in ICU
 - IC patrol team

Environmental cleansing

- Color coding
- Train the supporting staff
- For MDRO patients
 - After napkin change or bathing
 - Perform more frequently on high touch surface
 - Disposable wipe
- Regular culture screening
 - monthly
 - ATP (Adenosine Triphosphate) bioluminescent



Care Bundles

- Catheter associated blood stream infection (CABSI)
 - Already in place
 - *Bactiguard* for Central line insertion

<u>Questions/ Issues</u>	ICT	Dr. Perl:
1. GN resistance organisms in QEH	Previously MRPA was a challenge in QEH, its rate has been much reduced after implementation of targeted infection control program. Acinetobacter spp. now becomes the most difficult one to handle among all GN resistant organisms in QEH	Acinetobacter spp. is more difficult to control once it establishes its niche in the hospital environment, since it can survive in the environment for an extended period of time.
2. CVC Catheter	What is the view on Bactiguard CVC catheter? It has promoted as a very common used catheter in US, is it real?	Not familiar with the mentioned catheter

<p>3. Routine typing in HK</p>	<ul style="list-style-type: none"> ➤Molecular typing would be used for outbreaks / clustering of cases ➤In-house PFGE in the past but largely stopped due to suboptimal performance 	<p>It is recommend to perform typing to identify the transmission of GNR organisms</p>
<p>4. Problems on environmental cleaning</p>	<p>Dr. Lai (ICU consultant) said that it is hard to persuade staff to use <u>plastic keyboard cover</u>, lately he has purchased silicon covers for trial.</p>	<p>Computer keyboard is definitely an at-risk item and any attempt to keep it clean is worthwhile.</p>
<p>5. Antibiotic usage</p>	<p>Dr. Lai (ICU consultant) said that they would try to see if there is any difference in using Unasyn and Augmentin for initial antibiotic prescription on selection pressure of MDRA.</p>	

Acknowledgement

- Dr. Raymond Lai, COS (Microbiology)/ICO, PWH/ Cluster ICO, NTEC
- Infection Control Team, PWH
- Dr. Dominic Tsang, CICO, HA/ CCD (IC), KCC/ Cons (Path), QEH
- Infection Control Team, QEH/KCC